ADMA Biologics Inc $ADMA Shares Bought by American Century Companies Inc.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

American Century Companies Inc. grew its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 12.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,252,362 shares of the biotechnology company's stock after acquiring an additional 478,800 shares during the period. American Century Companies Inc. owned about 1.79% of ADMA Biologics worth $84,367,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ADMA. Envestnet Asset Management Inc. increased its stake in shares of ADMA Biologics by 68.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 60,004 shares of the biotechnology company's stock worth $1,029,000 after purchasing an additional 24,293 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics during the fourth quarter worth about $19,076,000. Summit Investment Advisors Inc. increased its stake in shares of ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after purchasing an additional 746 shares in the last quarter. Barclays PLC grew its stake in ADMA Biologics by 2.4% during the 4th quarter. Barclays PLC now owns 541,093 shares of the biotechnology company's stock valued at $9,279,000 after acquiring an additional 12,464 shares in the last quarter. Finally, Mariner LLC purchased a new stake in ADMA Biologics during the 4th quarter valued at about $573,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analyst Upgrades and Downgrades

ADMA has been the subject of several research reports. Raymond James Financial upped their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $27.67.

Insider Transactions at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director directly owned 94,830 shares in the company, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 455,621 shares of company stock worth $9,461,633. 3.50% of the stock is currently owned by insiders.

ADMA Biologics Trading Up 4.1%

Shares of ADMA Biologics stock traded up $0.70 during mid-day trading on Friday, hitting $17.80. The stock had a trading volume of 2,342,671 shares, compared to its average volume of 3,444,757. The firm has a 50-day moving average of $17.91 and a two-hundred day moving average of $18.87. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The firm has a market cap of $4.25 billion, a P/E ratio of 20.70 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period in the prior year, the business posted $0.13 EPS. The business's revenue for the quarter was up 13.8% compared to the same quarter last year. Sell-side analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.